BioTuesdays

Category - Markets

Audentes
Markets

WB starts Audentes Therapeutics at OP

William Blair initiated coverage of Audentes Therapeutics (NASDAQ:BOLD) with an “outperform” rating and $35 fair value estimate. The stock closed at $25 on Oct. 16. Analyst Raju Prasad writes that the company is taking...

October 17, 2017
Ardelyx
Markets

Leerink resumes coverage of Ardelyx at OP

Leerink resumed coverage of Ardelyx (NASDAQ:ARDX) with an “outperform” rating and $13 price target. The stock closed at $6.40 on Oct. 16. Analyst Seamus Fernandez writes that in the last nine months, the clinical...

October 17, 2017
Flex Pharma
Markets

Flex Pharma starts Phase 2 CMT trial

Flex Pharma (NASDAQ:FLKS) has initiated a Phase 2 double-blinded, parallel design trial in the U.S., known as COMMIT, to evaluate FLX-787, its co-activator of TRPA1 and TRPV1, in patients with Charcot-Marie-Tooth, who...

October 16, 2017
KalVista Pharmaceuticals Logo
Markets

BTIG ups KalVista price target to $27

BTIG raised its price target for KalVista Pharmaceuticals (NASDAQ:KALV) to $27 from $18 after the company inked a multifaceted collaboration with Merck (NYSE:MRK) last week. The stock closed at $9.74 on Oct. 13...

October 16, 2017
BioTime
Markets

BioTime prices $25-million stock offering

BioTime (NYSE MKT, TASE: BTX) priced a public offering of 9,615,385 common shares at a price of $2.60 each for gross proceeds of about $25-million. The offering is expected to close on Oct. 17. BioTime also granted...

October 13, 2017
Calithera Biosciences
Markets

WB starts Calithera at OP

William Blair launched coverage of Calithera Biosciences (NASDAQ:CALA) with an “outperform” rating. The stock closed at $16.05 on Oct. 5. “Continued clinical catalysts and a clear development path with the company’s...

October 6, 2017
Heska-Corporation-Logo
Markets

Canaccord starts Heska at buy

Canaccord Genuity initiated coverage of Heska (NASDAQ:HSKA) with a “buy” rating and price target of $115. The stock closed at $91.38 on Oct. 4. “Our survey work and checks suggest ongoing attractive market trends in...

October 5, 2017
Abeona Therapeutics Logo
Markets

Maxim ups Abeona price target to $35

Maxim Group raised its price target for Abeona Therapeutics (NASDAQ:ABEO) to $35 from $17, citing advances in the gene therapy space and comparatives to competitor, AveXis. “Given the valuation gap between these two...

October 5, 2017
Celsion
Markets

Maxim ups Celsion to buy

Maxim Group upgraded Celsion (NASDAQ:CLSN) to “buy” from “hold” with a $7 price target after the company renegotiate outstanding warrants, raising $15.6-million. Shares of Celsion were quoted at $4.96, down $1.09, or...

October 4, 2017
Myomo
Markets

HCW starts Myomo at buy

H.C. Wainwright initiated coverage of Myomo (NYSE MKT:MYO) with a “buy” rating and $12 price target. The stock closed at $6 on Sept. 29. Myomo is a wearable robotics company targeting a largely unmet need in providing a...

October 2, 2017